Centre for Clinical Infection and Diagnostics Research
CIDR a translational research facility set up as a joint initiative by GSTT and KCL in February 2011. The Centre comprises laboratory space, offices and lecture theatre/conference facilities. It is located on the St Thomas’ Hospital site adjacent to the routine diagnostic laboratories, the microbiology, virology, infectious diseases and infection prevention and control teams and the acute wards. It hosts clinicians and scientists with academic and service commitments, research nurses and epidemiologists. This co-location is a critical and distinctive success factor for CIDR, because it fosters the close collaborative working between service and research that is required for effective translational infectious diseases research. It brings insight into unmet clinical need, early warning for emerging pathogens, the ability to retrieve precious time-critical samples and to evaluate the benefit of new interventions with clinical staff at all levels who ultimately have to take up new practice.
Our mission is to conduct research that improves the prevention, diagnosis and treatment of infectious diseases relevant to our local population and beyond. Our research interest includes the prevention of hospital acquired infections and antimicrobial resistance, particularly established threats such as MRSA and C. difficile and more recently multi-drug resistant GNB including carbapenem-resistant organisms. A second important focus is the development and evaluation of novel diagnostics for bacterial and viral pathogens, both used in the laboratory and the wards at the point of care and clinical decision making. Diagnostics must meet the clinical need in an ever changing landscape. We aim to generate high quality evidence on clinical validity, utility, care pathway benefits and cost effectiveness of both laboratory-based and point-of-care diagnostics. We have experience with a wide range of technology platforms and have forged successful collaborations with industrial partners at all stages of product life cycle from proof-of-concept to introduction into routine service, including assay development, early evaluation and validation, clinical trials and health economic analyses.
We consider it important that our research benefits patients today, and for a number of years have provided advice to the Trust based on best practice, published guidance and our own research to guide infection prevention and control practice. We think the success of this focus is evidenced by GSTT having the lowest rates of C. difficile and MRSA across the Shelford Group of hospitals in 2012-2013.